Analysts Anticipate Stemline Therapeutics Inc (STML) Will Announce Quarterly Sales of $3.10 Million

Wall Street brokerages expect Stemline Therapeutics Inc (NASDAQ:STML) to post sales of $3.10 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Stemline Therapeutics’ earnings, with estimates ranging from $1.89 million to $4.30 million. The company is expected to issue its next earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that Stemline Therapeutics will report full year sales of $28.70 million for the current year, with estimates ranging from $14.91 million to $41.30 million. For the next fiscal year, analysts forecast that the firm will report sales of $103.28 million, with estimates ranging from $78.26 million to $128.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Stemline Therapeutics.

STML has been the topic of a number of recent research reports. Piper Jaffray Companies reissued an “overweight” rating on shares of Stemline Therapeutics in a research note on Wednesday, February 6th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. ValuEngine lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of Stemline Therapeutics in a research note on Wednesday, December 26th. Finally, BidaskClub raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, December 27th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.00.

NASDAQ STML opened at $12.85 on Friday. The firm has a market cap of $535.48 million, a price-to-earnings ratio of -4.30 and a beta of 1.12. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $20.55.

In related news, COO Kenneth Hoberman sold 13,547 shares of the business’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $10.15, for a total value of $137,502.05. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Ivan Bergstein sold 34,132 shares of the business’s stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $10.98, for a total value of $374,769.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,546 shares of company stock worth $2,185,917. Corporate insiders own 14.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Polar Capital LLP raised its holdings in shares of Stemline Therapeutics by 12.1% in the 4th quarter. Polar Capital LLP now owns 2,302,666 shares of the biopharmaceutical company’s stock valued at $21,875,000 after buying an additional 248,616 shares during the period. BlackRock Inc. raised its holdings in shares of Stemline Therapeutics by 4.9% in the 4th quarter. BlackRock Inc. now owns 2,065,239 shares of the biopharmaceutical company’s stock valued at $19,618,000 after buying an additional 95,747 shares during the period. Vanguard Group Inc raised its holdings in shares of Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after buying an additional 18,487 shares during the period. Vanguard Group Inc. raised its holdings in shares of Stemline Therapeutics by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock valued at $21,215,000 after buying an additional 18,487 shares during the period. Finally, Nexthera Capital LP raised its holdings in shares of Stemline Therapeutics by 4.0% in the 3rd quarter. Nexthera Capital LP now owns 582,070 shares of the biopharmaceutical company’s stock valued at $9,662,000 after buying an additional 22,553 shares during the period. Hedge funds and other institutional investors own 64.81% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Further Reading: How a Strangle Strategy is different from a Straddle Strategy

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.